Best Gene Editing CDMOs in United Kingdom
· updated as new inspection, certificate, and trial data enters the platform
3
CDMOs tracked
2
Fully scored
2
With FDA records
9
FDA inspections
12
EMA/MHRA GMP certs
Gene editing CDMOs support CRISPR, base, and prime editing programs — spanning guide RNA and nuclease (mRNA or protein) supply, delivery (LNP, AAV, or electroporation), and, for ex vivo programs, edited-cell manufacturing.
Because a gene-editing program touches several modalities at once, CDMO selection often hinges on which steps a partner covers in-house versus coordinates. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 5 NAI (no action), 4 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (7), France (4), Ireland (3), UNITED KINGDOM (3), Germany (2).
Last updated 2026-07-11. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
91.7 | 98.7 | 8 insp · 11 GMP | Limited | 0 programs |
| 2 |
RC
RoslinCT
Edinburgh, UK · Hopkinton, MA
|
80.2 | 98.8 | 1 insp · 1 GMP | Available | 0 programs |
| — |
Touchlight
Hampton, United Kingdom
|
Profiled | — | — | — | 0 programs |
What to evaluate in a Gene Editing CDMO
Editing components
Confirm supply of guide RNA and nuclease (Cas mRNA or protein) — in-house or sourced — and the quality controls on each.
Delivery modality
In vivo editing needs LNP or AAV delivery; ex vivo needs electroporation and cell handling. Match the CDMO's delivery experience to your approach.
Ex vivo cell manufacturing
For edited cell therapies, evaluate closed-system cell processing and chain-of-identity, as with other cell therapies.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
How has post-Brexit MHRA / EMA divergence affected UK CDMO selection?
Since 1 January 2021 the UK has operated MHRA as an independent regulator distinct from EMA. Practically this means: (1) UK manufacturing for EU-market supply requires a separate EMA GMP certificate, held by an EU-based Qualified Person; (2) EU manufacturing for UK-market supply requires MHRA acceptance, though MHRA has continued to recognize EMA GMP inspections under transitional arrangements; (3) the batches themselves may need to be released twice (once by an EU QP for EU supply, once by a UK QP for UK supply). CDMOs with UK + EU footprints are increasingly common in response; UK-only CDMOs need to arrange separate EU QP release for European supply. The Signal Score's Quality Compliance pillar captures both MHRA and EMA GMP certificates, so dual-jurisdiction CDMOs typically rank higher on this pillar.
Which UK CDMOs also cover FDA (US) regulatory geography?
UK CDMOs with US FDA inspection history qualify to supply US-market programs; those without FDA posture are limited to UK + EU. British CDMOs with FDA inspection density typically rank higher on the Signal Score's Quality Compliance pillar because that pillar aggregates FDA + EMA + MHRA data directly. Cross-check with the US region ranking — CDMOs appearing on both UK and US rankings have demonstrated multi-jurisdictional inspection posture, which materially reduces regulatory tech-transfer risk for programs supplying both markets.
How CDMO Signal identifies UK manufacturing presence
UK region attribution derives from each CDMO's declared facility locations. A location string containing UK-specific tokens (England, Scotland, Wales, Northern Ireland, London, Oxford, Cambridge, Liverpool, Manchester, Edinburgh, or 'UK'/'United Kingdom') places the CDMO in the UK region. Multi-site CDMOs appear in every applicable region — a Cambridge + Basel + Boston CDMO shows on UK, Europe, Switzerland, and USA rankings. Sponsors evaluating for a specific program should verify facility-level detail on the individual CDMO profile page — a CDMO with UK presence may only run some processes there and route others through their non-UK sites.
Gene Editing CDMOs — Frequently Asked Questions
Who are the top Gene Editing CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Gene Editing CDMOs include Charles River Laboratories, RoslinCT. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Gene Editing CDMOs have FDA inspection records?
CDMO Signal tracks 2 Gene Editing CDMOs with FDA inspection records and 12 EMA/MHRA GMP certificates across the group.
What should I look for in a gene editing CDMO?
Map the steps you need — guide RNA and nuclease supply, delivery (LNP/AAV/electroporation), and edited-cell manufacturing — and confirm which the CDMO covers in-house versus coordinates, plus a clean FDA and EMA/MHRA record.
Why do gene editing programs use multiple CDMOs?
A single program may need guide RNA, a nuclease, a delivery vehicle, and cell manufacturing — distinct capabilities. Some CDMOs cover several in-house; many programs combine specialists.
Related modalities